![]() |
市場調查報告書
商品編碼
1833581
2032 年手持式超音波市場預測:按感測器類型、軟體和連接性、資料管理功能、技術、應用、最終用戶和地區進行的全球分析Handheld Ultrasound Market Forecasts to 2032 - Global Analysis By Transducer Type, Software & Connectivity, Data Management Features, Technology, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球掌上超音波市場預計在 2025 年達到 4.02 億美元,到 2032 年將達到 10.3722 億美元,預測期內的複合年成長率為 14.5%。
掌上超音波是一種小型可攜式成像工具,旨在利用聲波捕捉器官、組織和血液循環的即時影像。與傳統超音波系統不同,它結構緊湊、操作靈活,方便床邊檢查和現場使用。它能夠快速提供診斷訊息,並支持醫護人員進行即時臨床評估。其多功能性使其成為急診醫學、加護治療和第一線醫療領域的寶貴工具,提高了重要診斷影像的可近性。
根據世界衛生組織(WHO)發布的數據,預計2022年全球將新增2,000萬名癌症病例。
慢性病增多
心血管疾病、糖尿病和癌症等慢性疾病的增多,推動了對攜帶式診斷解決方案的需求。手持式超音波設備擴大用於照護現場影像,以支持早期發現和持續監測。隨著全球人口老化,醫療保健系統正在轉向主動、個人化的照護模式。這種緊湊的影像工具使臨床醫生能夠在床邊進行評估,從而減少了昂貴且耗時的轉診需求。探頭小型化和人工智慧輔助影像解讀的技術進步正在提高診斷準確性。醫療保健的去中心化趨勢正在加速手持式超音波在醫院、診所和家庭中的普及。
有限的影像品質和高級功能
有限的處理能力和換能器功能限制了它們在複雜診斷場景中的應用。許多手持式型號尚未開發彈性成像、多普勒成像和3D重建等高級功能。這些限制可能會阻礙臨床決策,尤其是在急診室和手術室等高風險環境中。製造商面臨著在緊湊設計與高性能影像處理之間取得平衡的挑戰。這可能會減緩其在需要精確和全面可視化的專科領域的應用。
與遠端醫療和遠端患者監護的整合
掌上超音波與遠端醫療平台的融合開闢了遠距離診斷的新領域。醫生現在可以即時預約掃描並遠端解讀影像,從而改善醫療資源匱乏地區的就診體驗。與雲端基礎系統的整合實現了無縫資料共用和縱向患者追蹤。新興趨勢包括人工智慧驅動的影像分析和可連接智慧型手機的探頭,這些技術提高了非專業人士的易用性。這些創新在家庭醫療保健、鄉村診所和災難應變場景中尤其有用。隨著虛擬護理成為主流,掌上超音波有望成為遠端患者監護生態系統的基石。
資料安全和隱私問題
超音波影像的數位化引發了人們對患者資料保護的擔憂。無線傳輸和雲端儲存使敏感的醫療資訊面臨潛在的洩漏風險。要遵守《健康保險流通與責任法案》(HIPAA) 和《一般資料保護規範》(GDPR) 等法規,需要強大的加密和安全的存取通訊協定。小型製造商可能難以實施企業級網路安全措施,從而增加了其漏洞。人工智慧和物聯網的整合進一步加劇了資料管治的複雜性,尤其是在涉及第三方平台時。如果沒有嚴格的保障措施,人們對掌上超音波技術的信任可能會被削弱,從而推遲其在臨床工作流程中的應用。
新冠疫情加速了掌上超音波在快速床邊評估中的應用,尤其是在呼吸和心臟評估方面。醫院優先考慮攜帶式成像,以最大程度地減少患者出行並降低交叉污染的風險。雖然供應鏈中斷最初阻礙了設備的供應,但隨著臨床醫生尋求靈活的診斷工具,需求激增。監管機構迅速核准並授予緊急使用授權,為第一線醫療服務提供支援。這場危機也刺激了技術創新,例如無線探頭和非放射科醫生的人工智慧引導掃描。疫情過後,掌上超音波越來越被視為提供彈性和擴充性醫療服務的重要工具。
預計線性陣列部分將是預測期內最大的
線性陣列探頭因其在血管、肌肉骨骼和淺層器官成像方面的多功能性,預計將在預測期內佔據最大的市場佔有率。這些探頭在急診和門診護理中已成為必不可少的,因為它們能夠提供高解析度成像,用於表面診斷。波束成形和訊號處理技術的進步提高了清晰度和診斷可靠性。與行動平台的整合實現了即時影像共用和註釋。該細分市場受益於運動醫學、麻醉學和創傷護理領域日益成長的需求。隨著臨床應用的不斷擴展,線性陣列探頭在產量和技術創新方面繼續保持領先地位。
預計家庭醫療保健領域在預測期內將實現最高複合年成長率
預計家庭醫療保健領域將在預測期內呈現最高成長率。患者和看護者越來越有能力在遠端監督下進行基本掃描。緊湊易用且配備人工智慧引導的設備使超音波在臨床環境之外也普及。慢性病管理和人口老化正在推動家庭診斷的需求。穿戴式感測器與遠端醫療平台的整合正在增強護理的連續性。隨著報銷模式不斷發展以支援遠距服務,居家超音波正成為個人化醫療的關鍵推動力。
預計亞太地區將在預測期內佔據最大的市場佔有率,這得益於醫療基礎設施的不斷擴張和診斷需求的不斷成長。中國、印度和日本等國家正在投資可攜式成像技術,以彌合都市區醫療差距。政府推動數位醫療和本地製造的措施正在推動這些設備的普及。人工智慧超音波探頭和智慧型手機整合探頭在該地區迅速普及。全球原始設備製造商 (OEM) 與本地新興企業之間的策略合作夥伴關係正在加速技術創新並降低價格。在中階不斷壯大和醫療保健意識不斷增強的推動下,亞太地區將繼續成為手持式超音波的成長動力。
得益於其技術領先地位和強勁的研發投入,北美預計將在預測期內呈現最高的複合年成長率。美國和加拿大正在率先推出具有人工智慧診斷和雲端連接功能的智慧超音波系統。醫院正在將手持設備與電子健康記錄和遠端護理平台結合。監管機構正在簡化下一代診斷影像工具的核准,以鼓勵其加速商業化進程。該地區受益於強力的報銷政策和照護現場技術的廣泛採用。隨著精準診斷的發展勢頭強勁,北美將繼續引領手持超音波創新的標竿。
According to Stratistics MRC, the Global Handheld Ultrasound Market is accounted for $402.00 million in 2025 and is expected to reach $1037.22 million by 2032 growing at a CAGR of 14.5% during the forecast period. A handheld ultrasound is a small, portable imaging tool designed to capture live visuals of organs, tissues, and circulation using sound waves. Unlike conventional ultrasound systems, it is compact, highly mobile, and convenient for use in bedside examinations or field conditions. Offering rapid diagnostic insights, it supports healthcare providers in immediate clinical assessments. Its versatility makes it valuable in emergency medicine, intensive care, and frontline healthcare, improving accessibility to essential diagnostic imaging.
According to data published by the World Health Organization (WHO), there were an estimated 20.0 million new cancer cases globally in 2022.
Rising prevalence of chronic diseases
The growing burden of chronic illnesses such as cardiovascular disease, diabetes, and cancer is fueling demand for portable diagnostic solutions. Handheld ultrasound devices are increasingly used for point-of-care imaging to support early detection and ongoing monitoring. As global populations age, healthcare systems are shifting toward proactive and personalized care models. These compact imaging tools enable clinicians to perform bedside assessments, reducing the need for costly and time-consuming referrals. Technological advancements in probe miniaturization and AI-powered image interpretation are enhancing diagnostic accuracy. The trend toward decentralized healthcare is accelerating the adoption of handheld ultrasound across hospitals, clinics, and home settings.
Limited image quality and advanced features
Limitations in processing power and transducer capabilities restrict their use in complex diagnostic scenarios. Advanced features like elastography, Doppler imaging, and 3D reconstruction are still underdeveloped in many handheld models. These constraints can hinder clinical decision-making, especially in high-stakes environments like emergency rooms or surgical suites. Manufacturers face challenges in balancing compact design with high-performance imaging. As a result, adoption may be slower in specialties that demand precision and comprehensive visualization.
Integration with telemedicine and remote patient monitoring
The convergence of handheld ultrasound with telehealth platforms is opening new frontiers in remote diagnostics. Physicians can now guide scans in real-time and interpret images from afar, improving access in underserved regions. Integration with cloud-based systems allows seamless data sharing and longitudinal patient tracking. Emerging trends include AI-assisted image analysis and smartphone-connected probes that enhance usability for non-specialists. These innovations are particularly valuable in home healthcare, rural clinics, and disaster response scenarios. As virtual care becomes mainstream, handheld ultrasound is poised to become a cornerstone of remote patient monitoring ecosystems.
Data security and privacy concerns
The digitization of ultrasound imaging raises significant concerns around patient data protection. Wireless transmission and cloud storage expose sensitive health information to potential breaches. Compliance with regulations such as HIPAA and GDPR requires robust encryption and secure access protocols. Smaller manufacturers may struggle to implement enterprise-grade cybersecurity measures, increasing vulnerability. The integration of AI and IoT further complicates data governance, especially when third-party platforms are involved. Without stringent safeguards, trust in handheld ultrasound technology could be undermined, slowing its adoption in clinical workflows.
The COVID-19 pandemic accelerated the use of handheld ultrasound for rapid bedside assessments, especially in respiratory and cardiac evaluations. Hospitals prioritized portable imaging to minimize patient movement and reduce cross-contamination risks. Supply chain disruptions initially hampered device availability, but demand surged as clinicians sought flexible diagnostic tools. Regulatory bodies responded with expedited approvals and emergency use authorizations to support frontline care. The crisis also catalyzed innovation in wireless probes and AI-guided scanning for non-radiologists. Post-pandemic, handheld ultrasound is increasingly viewed as an essential tool for resilient and scalable healthcare delivery.
The linear arraysegment is expected to be the largest during the forecast period
The linear array segment is expected to account for the largest market share during the forecast period, due to its versatility in vascular, musculoskeletal, and superficial organ imaging. These probes offer high-resolution imaging for surface-level diagnostics, making them indispensable in emergency and outpatient settings. Advancements in beamforming and signal processing are improving clarity and diagnostic confidence. Integration with mobile platforms enables real-time sharing and annotation of images. The segment benefits from rising demand in sports medicine, anesthesiology, and trauma care. As clinical applications expand, linear array probes continue to lead in both volume and innovation.
The home healthcare segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the home healthcare segment is predicted to witness the highest growth rate, driven by the shift toward decentralized care. Patients and caregivers are increasingly empowered to perform basic scans under remote supervision. Compact, user-friendly devices with AI guidance are making ultrasound accessible beyond clinical environments. The rise of chronic disease management and aging populations is fueling demand for in-home diagnostics. Integration with wearable sensors and telehealth platforms is enhancing continuity of care. As reimbursement models evolve to support remote services, home-based ultrasound is becoming a key enabler of personalized medicine.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising diagnostic demand. Countries like China, India, and Japan are investing in portable imaging to bridge gaps in rural and urban care. Government initiatives promoting digital health and local manufacturing are boosting device penetration. The region is witnessing rapid adoption of AI-enabled ultrasound and smartphone-integrated probes. Strategic collaborations between global OEMs and regional startups are accelerating innovation and affordability. With a growing middle class and increasing healthcare awareness, Asia Pacific remains a powerhouse for handheld ultrasound growth.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by technological leadership and robust R&D investment. The U.S. and Canada are pioneering smart ultrasound systems with AI diagnostics and cloud connectivity. Hospitals are integrating handheld devices into electronic health records and remote care platforms. Regulatory agencies are streamlining approvals for next-gen imaging tools, encouraging rapid commercialization. The region benefits from strong reimbursement policies and high adoption of point-of-care technologies. As precision diagnostics gain momentum, North America continues to set the benchmark for handheld ultrasound innovation.
Key players in the market
Some of the key players in Handheld Ultrasound Market include GE HealthCare Technologies Inc., Healcerion Co., Ltd., Siemens Healthineers AG, EchoNous Inc., Koninklijke Philips N.V., Aco Healthcare Co., Ltd., Canon Medical Systems Corporation, DGH Technology, Inc., FUJIFILM Holdings Corporation, Dawei Group, Mindray Medical International Ltd., BMV AG, Butterfly Network Inc., CHISON Medical Technologies Co., Ltd., and Clarius Mobile Health Corp.
In September2025, GE HealthCare announced it has entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer's disease to meet the growing demand for MRI in personalized treatment planning.
In September2025, FUJIFILM Biotechnologies announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug substance for efgartigimod at the Holly Springs, North Carolina, site in 2028.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.